Proactive Investors - Run By Investors For Investors

Sativa Investments moves into Germany, one of Europe’s largest medical cannabis markets

The ultimate goal is for the Sativa Germany joint venture to sell CBD products supplied by Sativa from the UK
cbd oil
Medical cannabis sales in Germany are set to hit €64mln this year

Cannabis investment vehicle Sativa Investments PLC (NEX:SATI) is moving into Germany as it looks to exploit the growing demand for cannabinoid products in the country.

Germany is one of the largest medical cannabis markets in Europe following the government’s decision to approve its use by prescription last year.

READ: Sativa positions itself for ‘huge opportunity’ in medicinal cannabis

Sativa has formed a joint venture with Germany-based Lexamed which will secure German wholesale, import and export licences for the distribution of medicinal cannabis products.

The long-term plan is for the products sold by the newly established Sativa Germany to be supplied by Sativa’s UK arm.

That is subject to the company successfully applying for a Home Office Medicinal Cannabis licence, so for the time being the joint venture will source products from any jurisdiction where it is regulatorily accepted.

A Sativa office is being set up in Stuttgart which will sell CBD products supplied by its subsidiary, George Botanicals.

Sative is initially investing €80,000 into the joint venture, which will give it a 60% majority shareholding. This figure could rise up to €250,000 once the German licence has been granted.

‘Important step’

“Initially, Sativa Germany has secured office space in Stuttgart and are actively recruiting sales staff to exploit the growing demand for CBD products in Germany,” said chief executive and founder Geremy Thomas.

“Once regulatory compliances are met, Sativa will supply top quality medicinal cannabis products to the German market.”

He added: “This is an important step for the Company, as it allows an entry point into the key German market to help continue its seed to consumer strategy.”

View full SATI profile View Profile

Sativa Investments Timeline

Related Articles

cancer scan
January 03 2019
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult
LX2 analyzer
May 07 2019
Armed with promising study results and proven technology, LexaGene is getting ready to launch the LX2 Genetic Analyzer to underserved markets valued at an estimated US$40 billion
June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use